<PAGE>



EXHIBIT 99.1

[LOGO] ADVANCED BIOTHERAPY, INC.


                                Administration
                                --------------
                                6355 Topanga Canyon Boulevard, Suite 510
                                Woodland Hills, California  91367

                                Laboratories
                                ------------
                                9110 Red Branch Rd.
                                Columbia, MD   21045

                                Telephone 818-883-6716
                                Fax           818-883-3353
                                www.advancedbiotherapy.com


                             "FOR IMMEDIATE RELEASE"


                Advanced Biotherapy Inc. Inaugurates New Website


LOS  ANGELES--(BUSINESS  WIRE)--October  28,  2003 -- Advanced  Biotherapy  Inc.
(OTCBB:ADVB - News) -- a developer of pioneering antibody therapies for treating
severe and widespread autoimmune diseases - reported the inauguration of its new
website at http://www.advancedbiotherapy.com

         Mr.  Edmond  Buccellato,  the  Company's  Chief  Executive  Officer and
Chairman  of the  Board of  Directors,  stated  "The  website  is not only  more
contemporary  in design,  but also provides our  investors,  and the public,  an
up-to-date glance of current  developments.  We are now more accessible in terms
of electronic communications."

About Advanced Biotherapy

Advanced Biotherapy,  Inc., located in Los Angeles, with laboratories located in
Columbia,  Maryland, is pioneering the development of new antibody therapies for
treating  severe  and  widespread   autoimmune  diseases.   Its  investigational
therapies  attack  autoimmune  diseases at their source,  neutralizing  biologic
imbalances  that impair immune  system  function.  Core  technology is protected
under U.S.  patents and  patents  pending  for the  exclusive  use of a class of
antibodies  to the protein  known as  interferon-gamma  and  antibodies to other
proteins for treating a range of autoimmune diseases.

In addition to historical facts or statements of current condition, this website
and  its  various  pages  contain  forward-looking   statements  about  Advanced
Biotherapy,  Inc. Forward-looking statements provide our current expectations or
forecasts of future events. These may include statements  regarding  anticipated
scientific   progress  in  our  research  programs,   development  of  potential
pharmaceutical  products,  prospects  for  regulatory  approval,   manufacturing
capabilities, market prospects for our products, sales and earnings projections,
and other statements  regarding  matters that are not historical  facts. Some of
these  forward-looking  statements  may be identified by the use of words in the
statements such as  "anticipate,"


<PAGE>

"estimate,"  "expect," "project," "intend," "plan," "believe" or other words and
terms of similar  meaning.  Our performance and results could differ  materially
from  those  reflected  in  these  forward-looking  statements  due  to  general
financial,   economic,   regulatory  and  political   conditions  affecting  the
biotechnology and  pharmaceutical  industries as well as more specific risks and
uncertainties.  The risks and  uncertainties  which may affect the  development,
operations  and  results of our  business  include,  but are not  limited to the
following:  risks associated with clinical trials, the uncertainties of research
and product  development  programs,  the  uncertainties of obtaining  regulatory
approval to conduct United States' based clinical trials,  the  uncertainties of
the regulatory approval process, the risks of competitive products, the risks of
our current  capital  resources,  the  uncertainties  as to the  availability of
future capital and our future  capital  requirements,  and the risks  associated
with the extent and breadth of the Company's patent portfolio.  Discussion about
our  clinical  investigations  and the effect of the patents  issued and pending
involves  risks and  uncertainties,  including but not limited to the risks that
third  parties may be successful in  challenging  such patents;  or that granted
claims may be held invalid or interpreted differently by a court of law; or that
new  technologies  will be developed  that are superior in treating the diseases
targeted by Advanced Biotherapy,  Inc. Given these risks and uncertainties,  any
or all of these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such forward-looking  statements.  Furthermore, we do
not intend (and we are not  obligated)  to update  publicly any  forward-looking
statements.

You are advised to consult the Company's  public filings with the Securities and
Exchange  Commission for further  information about risks and uncertainties that
may  affect  the  Company  and the  results  or  expectations  expressed  in our
forward-looking  statements,  including the section captioned  "Factors That May
Affect The Company"  contained in the  Company's  Annual Report on Form 10-KSB/A
for the fiscal year ended December 31, 2002.

Contact:
     Advanced Biotherapy, Inc.
     Amy Buccellato, 818-883-6716
     www.advancedbiotherapy.com

